Introduction IMbrave150 established first-line atezolizumab plus bevacizumab as a global standard of care for unresectable hepatocellular carcinoma (HCC). We report exploratory analyses of association

Figshare2025-02-27 更新50

Serial changes of the tumor volume.

资源简介：

相关数据集